Nisa Investment Advisors LLC grew its holdings in shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) by 168.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,512 shares of the biopharmaceutical company’s stock after acquiring an additional 5,972 shares during the quarter. Nisa Investment Advisors LLC owned about 0.13% of BioSpecifics Technologies worth $542,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BSTC. Tower Research Capital LLC TRC grew its holdings in shares of BioSpecifics Technologies by 140.1% during the third quarter. Tower Research Capital LLC TRC now owns 485 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 283 shares in the last quarter. Meeder Asset Management Inc. lifted its position in BioSpecifics Technologies by 10.0% during the third quarter. Meeder Asset Management Inc. now owns 2,274 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 206 shares during the last quarter. Winfield Associates Inc. purchased a new position in BioSpecifics Technologies in the 3rd quarter worth approximately $268,000. Macquarie Group Ltd. purchased a new position in BioSpecifics Technologies in the 2nd quarter worth approximately $275,000. Finally, D. E. Shaw & Co. Inc. grew its stake in BioSpecifics Technologies by 96.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,769 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 3,319 shares in the last quarter. Hedge funds and other institutional investors own 61.96% of the company’s stock.

Shares of BioSpecifics Technologies stock opened at $56.50 on Tuesday. The firm has a market capitalization of $415.41 million, a PE ratio of 17.88 and a beta of 1.22. The business’s 50-day moving average price is $57.28 and its 200-day moving average price is $55.55. BioSpecifics Technologies Corp. has a 12 month low of $45.81 and a 12 month high of $73.31.

BioSpecifics Technologies (NASDAQ:BSTC) last released its earnings results on Friday, November 8th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.10. The company had revenue of $9.44 million during the quarter, compared to the consensus estimate of $8.86 million. BioSpecifics Technologies had a return on equity of 21.82% and a net margin of 64.23%. On average, analysts expect that BioSpecifics Technologies Corp. will post 3.27 EPS for the current year.

Several research firms have recently weighed in on BSTC. BidaskClub upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research report on Friday, January 17th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of BioSpecifics Technologies in a research report on Wednesday, November 20th. ValuEngine upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. Finally, Zacks Investment Research cut BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research note on Monday, January 13th.

BioSpecifics Technologies Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

See Also: Why does a company issue an IPO?

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.